伴髓系恶性转化的Shwachman-Diamond综合征患儿的临床特征及基因突变分析

安文彬; 刘超; 万扬; 常丽贤; 陈晓燕; 竺晓凡

doi:10.7499/j.issn.1008-8830.2001133

PDF(1535 KB)

HTML

中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (5) : 460-465. DOI: 10.7499/j.issn.1008-8830.2001133

论著·临床研究

伴髓系恶性转化的Shwachman-Diamond综合征患儿的临床特征及基因突变分析

安文彬^1,2,3, 刘超^1,2,3, 万扬^1,2,3, 常丽贤^1,2,3, 陈晓燕^1,2,3, 竺晓凡^1,2,3

作者信息 +

Clinical features and gene mutations of children with Shwachman-Diamond syndrome and malignant myeloid transformation

AN Wen-Bin^1,2,3, LIU Chao^1,2,3, WAN Yang^1,2,3, CHANG Li-Xian^1,2,3, CHEN Xiao-Yan^1,2,3, ZHU Xiao-Fan^1,2,3

Author information +

文章历史 +

摘要

目的探讨伴髓系恶性转化的Shwachman-Diamond综合征（SDS）患儿的临床特征及基因突变情况。方法采用二代测序方法检测11例伴髓系恶性转化的SDS患儿的基因突变情况，分析患儿的临床特征和基因突变谱。结果 11例SDS患儿中，9例（82%）表现为儿童难治性血细胞减少（RCC），1例（9%）为骨髓增生异常综合征（MDS）伴原始细胞增多（MDS-EB），1例（9%）为急性髓系白血病伴MDS相关改变（AML-MRC）。发生髓系恶性转化的中位年龄为48个月（范围：7个月~14岁）。5例（45%）患儿表现为单纯的血液系统异常。所有患儿均检测到SBDS基因突变，常见的突变形式为c.258+2T > C纯合突变（5例，45%）和c.184A > T+c.258+2T > C复合杂合突变（3例，27%）。SBDS基因新变异c.634_635insAACATACCTGT+c.637_638delGA和c.8T > C分别评级为"致病的"和"可能致病的"。转化为RCC和MDS-EB/AML-MRC的患儿3年预期总体生存率分别为100%、0%（P=0.001）。结论 SDS患儿可能以血液系统症状为唯一表现，临床应引起重视。恶性转化的类型与预后相关。

Abstract

Objective To study the clinical features and genetic mutations of children with Shwachman-Diamond syndrome (SDS) and malignant myeloid transformation. Methods Next-generation sequencing was used to analyze the gene mutations in 11 SDS children with malignant myeloid transformation, and their clinical features and genetic mutations were analyzed. Results Of the 11 children with SDS, 9 (82%) presented with refractory cytopenia of childhood (RCC), 1 (9%) had myelodysplastic syndrome with excess blasts (MDS-EB), and 1 (9%) had acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). The median age of onset of malignant myeloid transformation was 48 months (ranged 7 months to 14 years). Of the 11 children, 45% had abnormalities in the hematological system alone. Mutations of the SBDS gene were detected in all 11 children, among whom 5 (45%) had c.258+2T > C homozygous mutation and 3 (27%) had c.184A > T+c.258+2T > C compound heterozygous mutation. The new mutations of the SBDS gene, c.634_635insAACATACCTGT+c.637_638delGA and c.8T > C, were rated as "pathogenic" and "possibly pathogenic" respectively. The 3-year predicted overall survival rates of children transformed to RCC and MDS-EB/AML-MRC were 100% and 0% respectively (P=0.001). Conclusions SDS children may have hematological system symptoms as the only manifestation, which needs to be taken seriously in clinical practice. The type of malignant transformation is associated with prognosis.

导出引用

安文彬, 刘超, 万扬, 常丽贤, 陈晓燕, 竺晓凡. 伴髓系恶性转化的Shwachman-Diamond综合征患儿的临床特征及基因突变分析[J]. 中国当代儿科杂志. 2020, 22(5): 460-465 https://doi.org/10.7499/j.issn.1008-8830.2001133

AN Wen-Bin, LIU Chao, WAN Yang, CHANG Li-Xian, CHEN Xiao-Yan, ZHU Xiao-Fan. Clinical features and gene mutations of children with Shwachman-Diamond syndrome and malignant myeloid transformation[J]. Chinese Journal of Contemporary Pediatrics. 2020, 22(5): 460-465 https://doi.org/10.7499/j.issn.1008-8830.2001133

参考文献

[1] Nelson AS, Myers KC. Diagnosis, treatment, and molecular pathology of Shwachman-Diamond Syndrome[J]. Hematol Oncol Clin North Am, 2018, 32(4):687-700.
[2] Nelson A, Myers K. Shwachman-Diamond syndrome[EB/OL]. GeneReviews^®, (2018-10-18)[2020-01-25]. https://www.ncbi.nlm.nih.gov/pubmed/20301722.
[3] 王凤琦, 魏晓楠, 邵翠华, 等. Shwachman Diamond综合征的剪切位点突变及表型分析[J].青岛大学学报(医学版), 2018, 54(6):631-634.
[4] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
[5] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[6] Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation[J]. N Engl J Med, 2017, 376(6):536-547.
[7] Kuijpers TW, Alders M, Tool AT, et al. Hematologic abnormalities in Shwachman Diamond syndrome:lack of genotype-phenotype relationship[J]. Blood, 2005, 106(1):356-361.
[8] Dhanraj S, Matveev A, Li H, et al. Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome[J]. Blood, 2017, 129(11):1557-1562.
[9] Morini J, Nacci L, Babini G, et al. Whole exome sequencing discloses heterozygous variants in the DNAJC21 and EFL1 genes but not in SRP54 in 6 out of 16 patients with Shwachman-Diamond syndrome carrying biallelic SBDS mutations[J]. Br J Haematol, 2019, 185(3):627-630.
[10] Stepensky P, Chacón-Flores M, Kim KH, et al. Mutations in EFL1, an SBDS partner, are associated with infantile pancytopenia, exocrine pancreatic insufficiency and skeletal anomalies in a Shwachman-Diamond like syndrome[J]. J Med Genet, 2017, 54(8):558-566.
[11] Carapito R, Konantz M, Paillard C, et al. Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features[J]. J Clin Invest, 2017, 127(11):4090-4103.
[12] Mourad S, Bilodeau M, Roussy M, et al. IDH1 as a cooperating mutation in AML arising in the context of Shwachman-Diamond syndrome[J]. Front Oncol, 2019, 9:772.
[13] Myers KC, Furutani E, Weller E, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia:a multicentre, retrospective, cohort study[J]. Lancet Haematol, 2020, 7(3):e238-e246.
[14] Donadieu J, Fenneteau O, Beaupain B, et al. Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome[J]. Haematologica, 2012, 97(9):1312-1319.
[15] Alter BP, Giri N, Savage SA, et al. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up[J]. Haematologica, 2018, 103(1):30-39.
[16] Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy[J]. Blood, 2006, 107(12):4628-4635.
[17] Myers KC, Davies SM, Shimamura A. Clinical and molecular pathophysiology of Shwachman-Diamond syndrome:an update[J]. Hematol Oncol Clin North Am, 2013, 27(1):117-128.
[18] Cada M, Segbefia CI, Klaassen R, et al. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes[J]. Haematologica, 2015, 100(5):633-642.